Hydration Pharmaceuticals Co. Ltd. (AU:HPC) has released an update.
Hydration Pharmaceuticals Co. Ltd., known as Hydralyte, has successfully obtained a waiver from the ASX, allowing them to amend their financing agreement with PURE Asset Management without shareholder approval. This amendment provides Hydralyte with an additional A$1.7 million in funding and the potential for further tranches totaling A$3 million, accessible at PURE’s discretion. The revised terms also adjust the interest rates and introduce provisions for capitalizing interest and converting it into shares.
For further insights into AU:HPC stock, check out TipRanks’ Stock Analysis page.
